Tsuruya, Kazuhiko

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Heerspink, H. J. L., Jardine, M. J., Kohan, D. E., Lafayette, R., Levin, A., Liew, A., Zhang, H., Noronha, I. L., Mastroianni-Kirsztajn, G., Chow, S., et al. (2026) · The Lancet

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 12

Control Status of Atherosclerotic Cardiovascular Risk Factors Among Japanese High-Risk Subjects:Analyses of a Japanese Health Check Database from 2008 to 2011

Hasegawa, K., Tsukamoto, K., Kunimi, M., Asahi, K., Iseki, K., Moriyama, T., Yamagata, K., Tsuruya, K., Fujimoto, S., Narita, I., et al. (2016) · Journal of Atherosclerosis and Thrombosis

Health Promotion and Cardiovascular PreventionDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 10